Pandya, K.J., Dahlberg, S., Hidalgo, M., Cohen, R.B., Lee, M.W., Schiller, J.H. and Johnson, D.H. (2007) A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus [CCI-779] in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group [E1500]. Journal of Thoracic Oncology, 2, 1036-1041. http://dx.doi.org/10.1097/JTO.0b013e318155a439

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.